Effects of modern antitumor drug therapy possibilities to skin melanoma on oncological and epidemiological indicators in the Krasnoyarsk region

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: Deevelopment of new diagnostics and treatment of malignant neoplasms methods increase their efficiency, and safety is one of the most urgent tasks of modern oncology. Currently, targeted and immunotherapy contributes to the treatment of malignant neoplasms. One of the examples is the treatment of skin melanoma.

AIMS: This study aimed to investigate the influence of therapeutic tactics on epidemiological indicators in the morbidity of the skin melanoma.

MATERIALS AND METHODS: The study used data of the Krasnoyarsk territory cancer-register.

RESULTS: In the Krasnoyarsk territory from 2016 to 2020 registered 65,042 cases of malignant neoplasms, of which 30,532 cases (46.9%) reported among men and 34,510 cases (53.1%) among women. In the same period, registered 899 cases of skin melanoma, 343 cases among men (38.2%) and 556 cases among women (61.8%). The most important stage in the treatment of skin melanoma is the disease stage, because only favorable prognosis characteristic for early stages of the disease.

CONCLUSIONS: Routine using modern antitumor drug therapy in everyday clinical practice has significantly changed the results of skin melanoma treatment.

About the authors

Ruslan A. Zukov

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University

Author for correspondence.
Email: ethics.commitee@mail.ru
ORCID iD: 0000-0002-7210-3020
SPIN-code: 3632-8415

MD, Dr. Sci. (Med.), Professor

Russian Federation, Krasnoyarsk; Krasnoyarsk

Ivan P. Safontsef

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky RSBHE

Email: SIP@onkolog24.ru
ORCID iD: 0000-0002-8177-6788
SPIN-code: 1548-5565

MD, Cand. Sci. (Med.)

Russian Federation, Krasnoyarsk; Krasnoyarsk

Marina P. Klimenok

Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky RSBHE

Email: klimenok71@mail.ru
Russian Federation, Krasnoyarsk

Ekaterina N. Eremina

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky RSBHE

Email: eremina.catia2010@yandex.ru
SPIN-code: 4132-0336
Russian Federation, Krasnoyarsk; Krasnoyarsk

References

  1. State report «On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2020». Available from: https://www.rospotrebnadzor.ru/upload/iblock/5fa/gd-seb_02.06-_s-podpisyu_.pdf. (In Russ).
  2. Kaprin AD, Starynsky VV, Shahzadova AO., editors. Status of oncological assistance to the population of Russia in 2020 [Internet]. Moscow : MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii; 2021. (In Russ).
  3. Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Sur Оncol. 2018;25(8):2105–2110. doi: 10.1245/s10434-018-6513-7
  4. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–492. doi: 10.3322/caac.21409
  5. Vakhitova II, Michenko AV, Potekaev NN, et al. The prevalence of risk factors for development of melanoma among dermatological patients. Russian Journal of Clinical Dermatology and Venereology. 2020;19(5):630–636. (In Russ.). doi: 10.17116/klinderma202019051630
  6. Stang A, Jöckel KH. Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany cancer. Cancer. 2016;122(3):432–437. doi: 10.1002/cncr.29755
  7. Eremina EN, Karakhanyan AR, Vahraunin DA, et al. Molecular genetic markers of pigment melanoma of the skin (literature review). Siberian medical review. 2020;3:38–46. (In Russ). doi: 10.20333/2500136-2020-3-38-46
  8. Giunta EF, de Falco V, Napolitano S, et al. Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations. Ther Adv Med Oncol. 2020;12:1–15. doi: 10.1177/1758835920925219
  9. In GK, Poorman K, Saul M, et al. Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases. Oncotarget. 2020;11(33):3118–3128. doi: 10.18632/oncotarget.27686
  10. Vanni I, Tanda ET, Spagnolo F, et al. The Current state of molecular testing in the BRAF-mutated melanoma landscape. Front Mol Biosci. 2020;7:[about 16 p.]. Available from: https://www.frontiersin.org/articles/10.3389/fmolb.2020.00113. doi: 10.3389/fmolb.2020.00113
  11. Shain AH, Yeh I, Kovalyshyn I, et al. The Genetic evolution of melanoma from precursor lesions. N Engl J Med. 2015;373(20):1926–1936. doi: 10.1056/NEJMoa1502583
  12. Long GV, Flaherty KT, Stroyakovskiy D, Gogas H. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631–1639. doi: 10.1093/annonc/mdx176
  13. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma. Ann Oncol. 2016;27 Suppl. 6:vi552–vi587. doi: 10.1093/annonc/mdw435.37
  14. Robert С, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626–636. doi: 10.1056/NEJMoa1904059
  15. Long GV, Weber JS, Infante JR, et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol. 2016;34(8):871–878. doi: 10.1200/JCO.2015.62.9345
  16. Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976–1986. doi: 10.1056/NEJMoa1716078
  17. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–1894. doi: 10.1200/JCO.2014.56.2736
  18. Rosner S, Kwong E, Shoushtari AN, et al. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Med. 2018;7(3):690–697. doi: 10.1002/cam4.1356
  19. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–1982. doi: 10.1200/JCO.2014.59.4358
  20. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(13):1270–1271. doi: 10.1056/NEJMc1509660

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Dynamics of malignant skin melanoma newly detected cases in the Krasnoyarsk region in 2016–2020.

Download (44KB)
Indexing metadata
3. Fig. 2. Dynamics of malignant skin melanoma newly detected cases in Russia in 2016–2020.

Download (45KB)
Indexing metadata
4. Fig. 3. The malignant neoplasms morbidity structure in Krasnoyarsk region in 2020, %.

Download (143KB)
Indexing metadata
5. Fig. 4. Changes in morbidity of malignant melanoma skin in the Krasnoyarsk region, Siberian Federal District and Russian Federation in 2016–2020, per 100 thousand population.

Download (99KB)
Indexing metadata
6. Fig. 5. Changes in morbidity of malignant melanoma skin in the Krasnoyarsk region, among men and women, in 2016–2020, per 100 thousand of the corresponding population.

Download (75KB)
Indexing metadata
7. Fig. 6. Comparison of malignant melanoma morbidity by age groups in the Krasnoyarsk region in 2016 and 2020, per 100 thousand population.

Download (105KB)
Indexing metadata
8. Fig. 7. Changes in morbidity of malignant melanoma skin in the Krasnoyarsk region, by age groups, in 2016–2020, per 100 thousand population.

Download (145KB)
Indexing metadata
9. Fig. 8. Changes in detection of malignant skin melanoma in the Krasnoyarsk region by the prevalence of the malignant process (I–IV stages), %.

Download (84KB)
Indexing metadata

Copyright (c) 2021 Zukov R.A., Safontsef I.P., Klimenok M.P., Eremina E.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies